Achilles Therapeutics to Present at Upcoming Scientific Congresses
October 01 2021 - 7:00AM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, will present an oral presentation at the 2021
European Society for Gene and Cell Therapy (ESGCT) Congress being
held in a virtual format from October 19-22, 2021, and two posters
at the Society for Immunotherapy of Cancer (SITC) 36th Annual
Meeting being held in a hybrid format from November 10-14, 2021
online and in person in Washington, DC.
Details of the presentations are as follows:
- 2021 European Society for Gene and Cell Therapy (ESGCT)
CongressAbstract Title:
Multicentre, prospective research protocol for
development of a clonal neoantigen-reactive
T cell therapy pipeline across multiple tumour
typesPresentation Number:
OR54Session: 6c ManufacturingSession
Time: Friday, October 22, 2021: 9:00am–11:00am CEST
(3:00am–5:00am ET)Presenter: Michael Grant, MB,
BCh, BAO, BSc, PGCert, FHEA, Associate Medical Director,
Achilles TherapeuticsFull ESGCT abstract details will be available
October 19, 2021.
- Society for Immunotherapy of Cancer (SITC) 36th Annual
MeetingAbstract
Title: Sensitive quantification and
tracking of the active components of a Clonal Neoantigen T cell
(cNeT) therapy: From manufacture to peripheral
circulationPoster Number: 543Poster
Presenter: Samra Turajlic, MD, MBBS, MRCP, PhD, THETIS
Chief Investigator, Royal Marsden, London, UKAbstract
Title: The Achilles VELOS™ Process 2
boosts the dose of highly functional clonal neoantigen-reactive T
cells for precision personalized cell therapiesPoster
Number: 193Poster Presenter: Joseph
Robinson, PhD, Senior Scientist, Process Development, Achilles
TherapeuticsFull SITC abstract details will be available on
November 9, 2021 and posters will be available on November 12,
2021.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
unresectable locally advanced and metastatic non-small cell lung
cancer (NSCLC) and the THETIS trial in patients with recurrent or
metastatic melanoma. Achilles uses DNA sequencing data from each
patient, together with its proprietary PELEUS™ bioinformatics
platform, to identify clonal neoantigens specific to that patient,
and then develop precision T cell-based product candidates
specifically targeting those clonal neoantigens.
Forward-Looking StatementsThis
press release contains express or implied forward-looking
statements that are based on our management's belief and
assumptions and on information currently available to our
management. Although we believe that the expectations reflected in
these forward-looking statements are reasonable, these statements
relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Further information:
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Apr 2023 to Apr 2024